News & Blog

de Oliveira MG, Calmasini FB, Alexandre EC, De Nucci G, Mónica FZ, Antunes E. Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. Am J Physiol Renal Physiol. 2016 Apr 27:ajprenal.00041.2016. doi: 10.1152/ajprenal.00041.2016. [Epub ahead of print]

Investigators in this study aimed to test whether an experimental treatment known as BAY 58-2667 could have any potential benefit in the management of interstitial cystitis (IC). The treatment is thought to work by activating an enzyme called soluble guanylyl cyclase (sGC) that is implicated in a variety of medical conditions. Investigators studied the effects of BAY 58-2667 in female mice that were injected with another drug that induces cystitis. The investigators found that BAY 58-2667 prevented the changes in urination they saw in mice who did not receive the treatment. A variety of other laboratory markers were tested, and most pointed to the fact that the treatment had favorable effects in this mouse model of IC. Taken together, the findings suggest BAY 58-2667, and other similar agents that activate sGC, might represent a new and encouraging treatment approach for patients with IC, provided much more study is done.